213 related articles for article (PubMed ID: 10967573)
1. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.
Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C
Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
Sobecks RM; Le Beau MM; Anastasi J; Williams SF
Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
[TBL] [Abstract][Full Text] [Related]
3. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
[TBL] [Abstract][Full Text] [Related]
5. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
[TBL] [Abstract][Full Text] [Related]
6. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
[TBL] [Abstract][Full Text] [Related]
7. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
[TBL] [Abstract][Full Text] [Related]
8. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
9. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
11. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
12. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
13. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
[TBL] [Abstract][Full Text] [Related]
14. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
15. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.
Levine EG; Bloomfield CD
Semin Oncol; 1992 Feb; 19(1):47-84. PubMed ID: 1736370
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
17. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
19. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
[TBL] [Abstract][Full Text] [Related]
20. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
